Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
RSV
Biotech
Sanofi inks $1.15B buyout to boost RSV pipeline
Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing a phase 1 vaccine candidate to expand its RSV pipeline beyond mRNA.
Nick Paul Taylor
Jul 22, 2025 4:20am
Pfizer lets its RSV pipeline dry up in crowded space
Oct 29, 2024 11:23am
With trial win, Merck looks to take on Sanofi, AZ in RSV
Oct 17, 2024 6:00pm
Pfizer axes another RSV med picked up in $525M ReViral buy
Oct 8, 2024 4:58pm
Enanta's RSV antiviral crushes viral load in challenge study
Sep 26, 2024 7:43am
Vicebio hauls in $100M series B to push RSV shot through phase 1
Sep 23, 2024 3:00am
